GlassScriptPhysician profile
Kapil Dhawan
NPI 1558385997
$3,643.13
in general payments reported to CMS, 2019-2025
35 companies · $959 in 2025
The $959 reported for 2025 was more than what 77% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $289 · 2021: $558 · 2022: $217 · 2023: $648 · 2024: $319 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.32 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Inspire Medical Systems, INC. | $364.68 | 2024-2025 | Inspire |
| United Therapeutics Corporation | $325.26 | 2019-2025 | Tyvaso |
| Abbvie INC. | $311.90 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Glaxosmithkline, LLC. | $243.76 | 2019-2024 | Nucala, Trelegy Ellipta |
| Abiomed | $225.79 | 2025 | |
| Siemens Medical Solutions USA, INC. | $198.47 | 2023 | Cios Spin |
| Actelion Pharmaceuticals US, INC. | $197.55 | 2019-2023 | Uptravi, Opsumit |
| Allergan, INC. | $161.85 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $147.80 | 2019-2025 | Fasenra |
| Verona Pharma, INC. | $132.33 | 2025 | Ohtuvayre |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.13 | 2023 | Lifevest |
| Merck Sharp & Dohme LLC | $118.11 | 2019-2025 | Zerbaxa, Capvaxive, Pifeltro |
| Mylan Specialty L.P. | $89.38 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $86.47 | 2021-2025 | Dupixent |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $62.63 | 2019-2025 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $44.90 | 2019-2021 | |
| Harmony Biosciences LLC | $41.64 | 2020-2021 | |
| Genentech USA, INC. | $40.67 | 2019 | |
| Baxter Healthcare | $39.81 | 2022 | |
| Fisher & Paykel Healthcare INC | $34.49 | 2019-2025 | Fisher & Paykel Healthcare |
| Electromed, INC. | $34.36 | 2023-2025 | Smartvest |
| Sunovion Pharmaceuticals INC. | $25.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.82 | 2023 | |
| Paratek Pharmaceuticals, INC. | $24.34 | 2021 | |
| Insmed, INC. | $23.42 | 2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $20.65 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.37 | 2019 | |
| Vyera Pharmaceuticals, LLC | $18.93 | 2019 | |
| Philips North America LLC | $17.34 | 2024 | (Ak6) Vest Therapy |
| Advanced Respiratory, INC | $17.25 | 2019 | |
| Emd Serono, INC. | $16.33 | 2020 | |
| Amgen INC. | $14.67 | 2025 | Tezspire |
| Circassia INC. | $13.20 | 2019 | |
| Chiesi USA, INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kapil Dhawan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.